Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Comp-10 is a novel small molecule identified through structure-based screening that functions as a selective allosteric inhibitor of Inosine monophosphate dehydrogenase 2 (IMPDH2). It binds to the GTP allosteric domain of IMPDH2, mimicking the inhibitory action of phosphatidylinositol 3-phosphate (PI(3)P). Unlike existing IMPDH inhibitors such as mycophenolic acid (MPA), Comp-10 potently inhibits human IMPDH2 enzymatic activity (IC50 ~260 nM), selectively reduces IMPDH2 protein levels, and disrupts IMPDH2 filament formation, which MPA tends to stabilize. It has demonstrated significant reduction in cell growth across various hematological malignancy cell lines, including anaplastic large cell lymphoma (ALCL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL), including variants resistant to ALK inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Comp-10.